Table 2.
Overall response, AFP response, and failure pattern after treatment.
| IMRT + sorafenib (n = 36) | IMRT (n = 46) | P value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Overall response | 0.120 | ||
| CR | 0 (0.0) | 1 (2.2) | |
| PR | 22 (61.1) | 20 (43.5) | |
| SD | 10 (27.8) | 13 (28.3) | |
| PD | 4 (11.1) | 12 (26.0) | |
| AFP response | 0.003 | ||
| ≥20% | 22 (61.1) | 13 (28.3) | |
| <20% | 14 (38.9) | 33 (71.7) | |
| Failure pattern | |||
| In-field recurrence | 7 (19.4) | 16 (34.8) | 0.125 |
| Out-field recurrence | 14 (38.9) | 12 (26.1) | 0.216 |
| Distant metastasis | 6 (16.7) | 8 (17.4) | 0.931 |
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.